ClinicalTrials.gg
TerminatedNCT02110784Updated Sep 17, 2018

Eurartesim® in Patients With Imported Uncomplicated Plasmodium Vivax Malaria

A Phase 2 interventional study of Eurartesim tablets in Malaria, Vivax, sponsored by Alfasigma S.p.A.. Terminated at 13 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-09-17.

Sponsored by Alfasigma S.p.A. · Phase 2, Interventional, and Treatment

Why this study was terminated
Low recruitment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The aim of the present study is to investigate the efficacy, safety and tolerability of a therapeutic course of Eurartesim® in travellers who contracted malaria due to infection by P. vivax in endemic countries.

Read the detailed description

Vivax malaria occurs throughout the tropical, subtropical and some of the temperate latitudes globally. During a primary infection some P. vivax parasites become dormant in the liver (hypnozoites) during large periods of time and might subsequently cause multiple blood-stage relapses.

The asexual stages of P. vivax are generally still sensitive to chloroquine (CQ) throughout most of the world with the exception of Indonesia and Papua New Guinea where high therapeutic failure rates ranging from 5-84% have been reported. Also, there are reports of chloroquine failure from other countries and regions where the species is endemic; in particular, the presence of CQ-resistant vivax strains is now well described in several countries, including India, Brazil, Peru and Colombia.

The treatment of the dormant stages and the prevention of relapses is reached throughout the 8-aminoquinolines (primaquine is the only commercially available in this indication).

The current treatments recommended by World Health Organization (WHO) for the radical cure of CQ-resistant vivax malaria are Artemisinin based Combination Therapies (ACTs) with partner drugs having very long half-life, combined with a two weeks regiment of primaquine (WHO, 2010).

Among a variety of suitable artemisinin-based combinations, the fixed combination of dihydroartemisinin (DHA) and piperaquine (PQP )is considered an excellent therapeutic approach since it has got all the requirements considered essential for showing a positive benefit/risk ratio in malaria therapy.

Sigma-Tau i.f.r. S.p.A. has developed a DHA+PQP formulation (Eurartesim®) manufactured according to international Good Manufacturing Practice (GMP) standards and has recently received marketing authorization in Europe via a centralized procedure by the European Medicine Agency (EMA) for uncomplicated episodes of P. falciparum malaria.

A substantial amount of data have been collected in patients with uncomplicated P. falciparum malaria treated with the DHA+PQP combination. In addition, several studies have provided evidence of high cure rate in patients with P. vivax malaria treated with DHA+PQP, however, no data are available so far on efficacy and safety of the DHA+PQP treatment in patients with imported P. vivax malaria. Acquiring data is therefore of particular importance since malaria represents an important burden among all travel-acquired illnesses considering not only the number of cases (10-20% of the imported malaria cases are due to P. vivax infection) but also the potential of a fatal outcome.

The aim of the present study is to investigate the efficacy, safety and tolerability of a therapeutic course of Eurartesim® in travellers who contracted malaria due to infection by P. vivax in endemic countries. The results of such "proof of concept" study will be used for estimating the failure rate in a precise way and to dimension one or more subsequent phase III trials of comparative efficacy.

02

Conditions studied

  • Malaria, Vivax

Browse trials for

Keywords

  • Artemisinin based Combination Therapies
  • eurartesim
  • Dihydroartemisinin/Piperaquine
03

In context

Malaria, Vivax

124 studies on the registry are indexed under Malaria, Vivax; 20 are open to participants now.

This study's enrollment of 27 is below the median of 150 across 104 interventional studies indexed under Malaria, Vivax.

Browse Malaria, Vivax studies →

Lead sponsor

Alfasigma S.p.A. is the lead sponsor of 24 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have read the Information for the Patient and signed the Form;
  • Aged ≥18 years and able to swallow oral medication;
  • Body weight comprised between 24 kg and 100 kg (included) for males and females;
  • Uncomplicated malaria with microscopically confirmed monoinfection by Plasmodium vivax or mixed infection (i.e. infection with P. vivax and other Plasmodium species);
  • Willingness to comply with the study protocol and the study visit schedule.

Exclusion criteria

Exclusion Criteria:

  • Participation in any drug study during the previous 30 days;
  • Antimalarial treatment with chloroquine and quinine within the previous 6 weeks, with piperaquine-based compounds or mefloquine or lumefantrine within the previous 3 months and with halofantrine within the previous 30 days prior to screening;
  • P. vivax/Plasmodium species asexual stage parasitaemia ≥ 5% Red Blood Cells (in cases of mixed infection);
  • Clinical and/or laboratory features of severe malaria according to WHO criteria (WHO 2010);
  • abnormality that requires urgent management (i.e. arrhythmias, Atrio-Ventricular block II and III degree etc.);
  • Family history of sudden death, or known congenital prolongation of the
  • Lengthening of QT interval on ECG: corrected QT interval (Fridericia's correction) ≥450 ms for males and ≥470 ms for females;
  • Concomitant administration of any treatment which can induce a lengthening of QT interval (i.e. antihistamines, macrolides, etc.) and of any antimalarial drugs (for the full list of prohibited drugs refer to section 8.3);
  • Any to blood sampling (i.e. important haemorrhagic diathesis);;
  • Presence of intercurrent illness or any condition (i.e. severe vomiting and dehydration) which in the judgement of the Investigator would place the patient at undue risk or interfere with the study results;
  • Hypoglycaemia (blood glucose levels \< 2.2 mmol/L or \< 40 mg/dL);
  • Splenectomy;
  • Pregnant or lactating women. During the study period (Day 0- Day 42), fertile women who are sexually active must use an adequate method. They should utilize oral or patch contraceptives, contraceptive implant or depot injection or an intrauterine device from at least one month before screening and during the whole study period. In all the other cases they have to agree to remain inactive or use condoms with a spermicidal agent during the study period;
  • Presence of jaundice;
  • Known renal impairment (serum creatinine > 2X the upper limit of the hospital laboratory reference range);
  • Known liver insufficiency ( and/or ALT > 3X the upper limit of the hospital laboratory reference range);
  • Relevant anaemia (\< 8 g/dL).
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Eurartesim tablets

    Eurartesim 320 mg piperaquine / 40 mg dihydroartemisinin film coated tablets. one or more tablets according to the body weight, once a day dor three consecutive days.

    Drug: Eurartesim tablets

Interventions

  • DrugEurartesim tablets

    Drug pages: Artenimol · Piperaquine

    dosage bands: 24 to \<36 kg body weight: 2 tablets a day for three consecutive days 36 to \<75 kg body weight: 3 tablets a day for three consecutive days 75 to 100 kg body weight: 4 tablets a day for three consecutive days

    Also known as: dihydroartemisinin/Piperaquine

06

What researchers measure

Primary outcomes

  1. Uncorrected adequate clinical and parasitological response (ACPR)

    The uncorrected ACPR will be considered met for all those patients that are not presenting parasitaemia and fever at day 21 follow-up visit.

    Time frame: 21 days after the start of treatment

Secondary outcomes

  1. Proportion of aparasitaemic patients

    to evaluate efficacy of the treatment to clear blood from parasites

    Time frame: at day 1, 2, 3, 7, 21, 42

  2. Proportion of afebrile patients

    to evaluate the efficacy of eurartesim in reducing fever caused by malaria

    Time frame: at day 1, 2, 3, 7, 21, 42

  3. uncorrected ACPR

    Time frame: at day 42

  4. Number of Patients with Serious and Non-Serious Adverse Events

    Time frame: up to 42 days from starting of treatment

07

Study locations

13 sites
  • Hôpital St André-CHU, Médecine interne et Maladies tropicales
    Bordeaux Cedex, France
  • Medizinische Klinik mit Schwerpunkt Infektiologie, Charite/Campus Virchow-Klinikum
    Berlin, Germany
  • Department of Infectious Diseases & Tropical Medicine, University of Munich
    Munich, Germany
  • 15. The Center for Geographic Medicine and Tropical Diseases, Department of Medicine C - The Chaim Sheba Medical Center
    Tel Hashomer, Israel
  • Clinica di Malattie Infettive e Tropicali, Universitá di Brescia
    Brescia, Italy
  • Azienda ospedaliera Luigi Sacco
    Milano, 20157, Italy
  • Azienda Ospedaliera Arcispedale S. Maria Nuova IRCCS - Dip. Medicina Interna e Spec. Mediche
    Reggio Emilia, 42123, Italy
  • Centro di Malattie Tropicali - INMI Spallanzani
    Roma, Italy
  • Dep. Infectious Disease, Section Travel Medicine, Leiden University Medical Centre
    Leiden, Netherlands
  • CRESIB-Hospital Clinic, Barcelona
    Barcelona, Spain
  • Hospital Vall d'Hebron, Barcelona
    Barcelona, Spain
  • Medical and Diagnostic Service Department, Swiss Tropical and Public Health Institute
    Basel, Switzerland
  • Bern University Hospital
    Bern, Switzerland
08

References and documents

Publications

  • Hasugian AR, Purba HL, Kenangalem E, Wuwung RM, Ebsworth EP, Maristela R, Penttinen PM, Laihad F, Anstey NM, Tjitra E, Price RN. Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. Clin Infect Dis. 2007 Apr 15;44(8):1067-74. doi: 10.1086/512677. Epub 2007 Mar 5. PubMed 17366451 ↗
  • Ratcliff A, Siswantoro H, Kenangalem E, Maristela R, Wuwung RM, Laihad F, Ebsworth EP, Anstey NM, Tjitra E, Price RN. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet. 2007 Mar 3;369(9563):757-765. doi: 10.1016/S0140-6736(07)60160-3. PubMed 17336652 ↗
  • Sinclair D, Gogtay N, Brand F, Olliaro P. Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria. Cochrane Database Syst Rev. 2011 Jul 6;(7):CD008492. doi: 10.1002/14651858.CD008492.pub2. PubMed 21735431 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2014 to primary completion in Nov 2016, 29 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2014
First posted
Apr 10, 2014
StartActual
Jun 18, 2014
Primary completionActual
Nov 23, 2016
CompletionActual
Apr 30, 2017
Last update
Sep 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02110784
Lead sponsor
Alfasigma S.p.A.
Responsible party
Sponsor
First posted
Apr 10, 2014
Start date
Jun 18, 2014
Primary completion
Nov 23, 2016
Completion
Apr 30, 2017
Last update
Sep 17, 2018

Study contacts

Christoph Hatz, Prof Dr Med
study chair · Medical and Diagnostic Service Department, Swiss Tropical and Public Health Institute, Basel - Switzerland

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Artenimol · Piperaquine

Start the discussion